Enhanced antitumor immunity of nanoliposome-encapsulated @entity1457 protein 70 peptide complex derived from XXXX fusion cells.

@entity1 @entity0 @entity2285 @entity5 @entity1457
UNASSIGNED: Tumor-derived @entity1457 proteins peptide complex (HSP.PC-Tu) has been regarded as a promising antitumor agent. However, inadequate immunogenicity and low bioavailability limit the clinical uses of this agent. In a previous study, we first produced an improved @entity2285 .PC  -based vaccine purified from dendritic cell (DC)- @entity5 fusion cells ( @entity2285 .PC-Fc) which had increased immunogenicity due to enhanced antigenic @entity5 peptides compared to @entity2285 .PC-Tu. In order to increase the bioavailability of @entity2285 .PC-Fc, the peptide complex was encapsulated with nanoliposomes (NL- @entity2285 .PC-Fc) in this study. After encapsulation, the @entity5 immunogenicity was observed using various assays. It was demonstrated that the NL- @entity2285 .PC-Fc has acceptable stability. The in  vivo antitumor immune response was increased with regard to T-cell activation, CTL response and @entity5 therapy efficiency compared to that of @entity2285 .PC-Fc. In addition, it was shown that DC maturation was improved by NL- @entity2285 .PC-Fc, which added to the antitumor immunity. The results obtained for NL- @entity2285 .PC-Fc, which improved immunogenicity and increases the bioavailability of @entity2285 .PC, may represent superior @entity1457 proteins  (HSPs)-based @entity5 vaccines. Such vaccines deserve further investigation and may provide a preclinical rationale to translate findings into early phase trials for @entity1 with @entity0 .
